Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro.

Abstract

BACKGROUND:

EpCAM is highly expressed on membrane of epithelial tumor cells and has been detected as soluble/secreted (sEpCAM) in serum of cancer patients. In this study we established an ELISA for in vitro diagnostics to measure sEpCAM concentrations in ascites. Moreover, we evaluated the influence of sEpCAM levels on catumaxomab (antibody)--dependent cellular cytotoxicity (ADCC).

METHODS:

Ascites specimens from cancer patients with positive (C+, n = 49) and negative (C-, n = 22) cytology and ascites of patients with liver cirrhosis (LC, n = 31) were collected. All cell-free plasma samples were analyzed for sEpCAM levels with a sandwich ELISA system established and validated by a human recombinant EpCAM standard for measurements in ascites as biological matrix. In addition, we evaluated effects of different sEpCAM concentrations on catumaxomab-dependent cell-mediated cytotoxicity (ADCC) with human peripheral blood mononuclear cells (PBMNCs) and human tumor cells.

RESULTS:

Our ELISA showed a high specificity for secreted EpCAM as determined by control HEK293FT cell lines stably expressing intracellular (EpICD), extracellular (EpEX) and the full-length protein (EpCAM) as fusion proteins. The lower limit of quantification was 200 pg/mL and the linear quantification range up to 5,000 pg/mL in ascites as biological matrix. Significant levels of sEpCAM were found in 39% of C+, 14% of C- and 13% of LC ascites samples. Higher concentrations of sEpCAM were detectable in C+ (mean: 1,015 pg/mL) than in C- (mean: 449 pg/mL; p = 0.04) or LC (mean: 326 pg/mL; p = 0.01). Soluble EpCAM concentration of 1 ng/mL significantly inhibited ADCC of PBMNCs on EpCAM overexpressing target cells.

CONCLUSION:

Elevated concentrations of sEpCAM can be found in a subgroup of C+ and also in a small group of C- patients. We consider that sEpCAM levels in different tumor entities and individual patients should be evaluated prior to applying anti-EpCAM antibody-based cancer therapies, since sEpCAM neutralizes catumaxomab activity, making therapy less efficient.

• Authors: Andreas Seeber, Agnieszka Martowicz, Gilbert Spizzo, Thomas Buratti, Peter Obrist, Dominic Fong, Guenther Gastl, Gerold Untergasser
• Journal: BMC cancer (BMC Cancer) Vol. 15 Pg. 372 (May 07 2015) ISSN: 1471-2407 [Electronic] England
• PMID: 25947366 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Bispecific
• Antigens, Neoplasm
• Cell Adhesion Molecules
• EPCAM protein, human
• Epithelial Cell Adhesion Molecule
• catumaxomab

Topics

• Antibodies, Bispecific (pharmacology)
• Antigens, Neoplasm (metabolism)
• Ascites (metabolism, pathology)
• Cell Adhesion Molecules (metabolism)
• Cell Line, Tumor
• Cell Proliferation (drug effects)
• Cytotoxicity, Immunologic
• Epithelial Cell Adhesion Molecule
• HEK293 Cells
• Humans
• Liver Cirrhosis (pathology)
• Neoplasms (pathology)
• Retrospective Studies